CARE™ at ASH 2022 Conference Report

[Le contenu qui suit est présenté dans sa langue originale : Anglais]


The CARE™ at ASH 2022 event was held on December 9th 2022, both virtually and in-person at the NOPSI Hotel in New Orleans, Louisiana. Canadian hematologists contextualized recent international news and data in hematology framing the news from a Canadian perspective.

Acute Myeloid Leukemia

Dr. Kareem Jamani — University of Calgary, Tom Baker Cancer
Recap of Presentation

Newly Diagnosed AML: Diagnostic and Treatment Algorithm

  • Eligible for intensive induction
  • Ineligible for intensive induction
    • Focus on both patient and AML; current treatments, and ASH updates that might impact treatment options
Access Presentation Video, SlidesAML Guidance

Benign: Hemostasis

Dr. Michelle Sholzberg — St. Michael’s Hospital
Recap of Presentation

Provide a snapshot of non-malignant heme at ASH 2022

  • Von Willebrand Disease – most prevalent inherited bleeding disorder
  • Addressing Iron Deficiency 
  • Reproductive health needs in patients with bleeding disorders
  • Immuno hematology

Von Willebrand disease (VWD)

  • Learnings about the lived experiences with Von Willebrand disease (VWD)
  • Barriers to care
  • Multifaceted negative impact of structural sexism in bleeding disorders’ management 
  • Review constructive directions
Access Presentation Video, Slides, Q&A

Benign: VTE

Dr. Wendy Lim — McMaster University
Recap of Presentation
  • Advances in our understanding of LMWH dosing for pregnancy prophylaxis and lack of benefit for anticoagulant prophylaxis for preventing pregnancy loss in women with recurrent miscarriage and thrombophilia
  • COVID-19 in patients with cancer is associated with ~3% risk of thrombosis at 30 days and elevated biomarkers (VWF, FVIII) can associated with increased risk; no increase in VTE risk with COVID vaccination compared with influenza vaccination
  • VEXAS syndrome is associated with increased thrombotic risk
Access Presentation Video, Slides, Q&A

Chronic Lymphocytic Leukemia

Dr. Carolyn Owen — University of Calgary
Recap of Presentation
  • Key News This Year: approval VO
  • How we approach therapy for CLL in 2022
  • Where is the “unmet need” in CLL today?
    • Is FCR still appropriate for young fit and good risk?  (CLL13/GAIA)
    • VO vs BTKi frontline in unmutated IgHV, any survival difference depending on sequencing?
    • Can we do even better with BTKi/BCL2i combos frontline?
    • What to do about patients who fail both BTKi AND BCL2i (particularly those who fail both covalent and non-covalent BTKi)?
    • How do we treat Richter’s Transformation?
  • Considerations for CLL Treatment During COVID-19 
    • Take into account local infection rates and risk to the patient of contracting COVID-19. 
    • Encourage patients to be current with approved COVID-19 vaccinations. 
    • Therapeutic decisions should remain to be based on individual factors such as symptom burden and comorbidities, along with molecular and cytogenetics abnormalities. 
    • If patients are currently on OTT without complications, they should maintain on the same therapy 
    • If a patient acquires COVID while on treatment, interrupt therapy when feasible, delay until symptoms resolve and tests are negative. Continuing with treatment may be warranted. 
    • Healthcare professionals should be aware of their local variant proportions, discuss risk of contracting COVID-19 with immunocompromised individuals, and advise them to seek immediate medical attention if they develop COVID-19 symptoms. 
      • EVUSHELD™, a monoclonal antibody, is authorized as pre-exposure prophylaxis to prevent COVID-19 in people who have moderate to severe immune compromise. EVUSHELD™ can also be used by those for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) or its component(s).
Access Presentation Video, Slides, Q&ACLL Guidance

Lymphoma (CAR T)

Dr. Michael Jain — Moffitt Centre, Tampa
Recap of Presentation


  • Second line DLBCL – Three RCTs of CAR T cells (ZUMA-7, BELINDA, TRANSFORM)
  • Axi-cel and tisa-cel are available in the 3+ line setting
  • Patients relapsing within 12 months of R-CHOP have poor outcomes with standard second line therapy followed by auto-SCT
  • High tumor burden, and high CAR-HEMATOTOX scores lead to poorer outcomes after CAR T. Do not let systems factors worsen these!
  • Retrospective (registry) and 2L trial data suggest axi-cel more effective than tisa-cel


  • Brexu-cel soon to be available for BTK-resistant MCL
  • Tumor intrinsic factors (p53, complex karyotype affect outcome)

In FL:

  • CAR T cell therapy not available (outside of trial)

In Myeloma:

  • CAR T cell therapy not available (outside of trial)
Access Presentation Video, Slides, Q&A

Lymphoma (Non-CAR T)

Dr. John Kuruvilla — Princess Margaret Cancer Centre
Dr. John Kuruvilla
Recap of Presentation

Novel therapy comes of age!

  • Novel therapy demonstrates significant benefit in the primary treatment setting
    • DLBCL (PFS: Polarix)
    • cHL (OS: ECHELON-1)
  • CAR-T cell therapy increasingly established in DLBCL with strong data in MCL (FL)
  • Anti-PD1 antibodies confirm benefit in RR-cHL and move into frontline
    • S1826/HDC1 completes accrual (Nivo or BV with AVD in stage III/IV cHL)
  • Bispecific antibodies (CD3/CD20) show significant single agent activity in RR-DBCL and RR-FL
    • Glofitamab, Mosunetuzumab, Epcoritamab, Odronextamab
  • BTKi trials (frontline MCL; RCTs in WM) deliver favourable results for new treatments
Access Presentation Video, Slides, Q&AHL Guidance

Plasma Cell Dyscraisas

Dr. Hira Mian — McMaster University
Recap of Presentation
  • What do our outcomes currently look like? Mian et al. CLML 2022
  • Precursor to MM Disease stages
  • Current Landscape of Treatment in Multiple Myeloma in Canada
    • Drugs coming down the pipeline
    • We need to catch up from access end
      • RVD to quadruplet therapy / Bispecifics / CART therapy
      • How will we sequence? How will we pay?
Access Presentation Video, Slides, Q&A

Thank You To Our Sponsors!


Source material is identified and acknowledged. ASCO is a registered trademark of the American Society of Clinical Oncology. ASH is short form for American Society of Hematology. EHA is short form European Hematology Association. Viewers are cautioned that ASCO, ASH and EHA have in no way approved, reviewed or endorsed the contents of the attached material.


CARE™ receives funding at arm’s length from multi-industry sponsors, institutions and research associations. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsors. Program content is developed independently of sponsors. This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and for further investigation.

CARE™ PUBLICATIONS provides educational updates on current trends in medicine. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsor(s). Program content is developed independently of sponsor(s). This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and further investigation. Decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources. Opinions expressed herein reflect the opinions and analyses of the experts who have authored the material. Support for the distribution of this report was provided by AbbVie, AstraZeneca, BeiGene, Incyte, Kite (a Gilead Company), Hoffmann-La Roche, Seagen, and Sobi. Copyright © 2022 by CARE™. All rights reserved. This publication or any portion thereof, in print, electronic copy or any other form, cannot be reproduced without the express written consent of CARE™. Any information, data, analysis, or results reproduced from another source remains the property of its authors. CARE™ is a registered trademark. Canada (Registration No. TMA931,165). United States of America (Registration No. 5,024,819).